NCT00038376View on ClinicalTrials.gov

Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

May 8, 1990

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions
Lymphoma, T-CellMycosis FungoidesHematologic Neoplasms
Interventions
DRUG

Isotretinoin (Accutane)

0.5 mg/k (1.0 mg/k total) by mouth twice a day

DRUG

Interferon Alpha

Starting dose of 3 MU injected under skin once a day for 12 weeks.

Trial Locations (1)

77030

M. D. Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER